<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6114">
  <stage>Registered</stage>
  <submitdate>8/08/2016</submitdate>
  <approvaldate>8/08/2016</approvaldate>
  <nctid>NCT02862548</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant</studytitle>
    <scientifictitle>A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Subjects With Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-320-3912</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TAF
Treatment: drugs - TDF

Experimental: TAF - TAF for 48 weeks

Active Comparator: TDF - TDF alone or in combination with other approved antivirals per local practice for 48 weeks

Experimental: Optional Treatment Extension Phase - After Week 48, participants will be eligible to receive TAF for an additional 96 weeks.


Treatment: drugs: TAF
25 mg tablet administered orally once daily

Treatment: drugs: TDF
300 mg tablet administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) of TAF 25mg Once Daily Versus TDF-Containing Regimens Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of Participants with HBV DNA &lt; 20 IU/mL at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)</outcome>
      <timepoint>Baseline; Weeks 24 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Creatinine</outcome>
      <timepoint>Baseline; Weeks 24 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum eGFR_CKD-EPI</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants with HBV DNA &lt; 20 IU/mL at Week 48</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Must have the ability to understand and sign a written informed consent form; consent
             must be obtained prior to initiation of study procedures

          -  Documented evidence of chronic HBV infection prior to transplantation

          -  Primary or secondary (re-transplant), liver alone or liver and kidney transplant
             recipient from deceased or living donor

          -  Liver Transplant = 12 weeks prior to screening

          -  Maintained on TDF alone or in combination with other approved antivirals for HBV
             prophylaxis or treatment

          -  Have been on approved HBV oral antiviral (OAV) treatment for at least 12 weeks
             post-transplant prior to screening, with HBV DNA &lt; lower limit of quantification
             (LLOQ) at screening

          -  Screening eGFR_CKD-EPI &lt; 90 ml/min/1.73m2

          -  Male participants and female participants of childbearing potential who engage in
             heterosexual intercourse must agree to use protocol specified method(s) of
             contraception

          -  Women considered of child bearing potential must have a negative serum pregnancy test
             at Screening and a negative urine test at Baseline before dosing

          -  Must be willing and able to comply with all study requirements

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Multi-organ transplant that includes heart or lung recipient (participants who have
             their liver transplant as part of a liver-kidney dual transplant are eligible to
             enroll)

          -  Participants with history of de novo or recurrent hepatocellular carcinoma (HCC)
             post-transplant and at screening

          -  Histological evidence of unresolved transplant rejection

          -  Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy,
             hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated
             cirrhosis

          -  Participants meeting any of the following laboratory parameters at screening:

               -  Alanine aminotransferase (ALT) &gt; 10× the upper limit of normal (ULN)

               -  International normalized ratio (INR) &gt; 1.5 × ULN unless the participant is stable
                  on anticoagulant regimen affecting INR

               -  Albumin &lt; 3.0 g/dL

               -  Direct bilirubin = 4 × ULN

               -  Platelet count &lt; 50,000/mL

          -  Co-infection with HIV or hepatitis C virus (HCV)

          -  Recent (within 4 weeks of Screening) episode or infection requiring systemic
             antibiotics

          -  Use or planned use of T-cell depleting/masking antibodies, systemic antineoplastic
             agents, cyclosporine &gt; 300 mg/day, or use of any prohibited medications listed within
             28 days of the Baseline/Day 1 visit

          -  Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are cured by surgical resection (e.g., basal cell skin cancer, etc.) or
             hepatocellular carcinoma. Participants under evaluation for possible malignancy are
             not eligible

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Use of investigational agents within 3 months of screening, unless allowed by the
             Sponsor

          -  Use of any prohibited medications

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with participant compliance

          -  Known hypersensitivity to study drugs, metabolites or formulation excipients

          -  Lactating females or those who may wish to become pregnant during the course of the
             study

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>51</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objectives of this study are to evaluate the safety, tolerability, and efficacy
      of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens
      in participants with chronic hepatitis B virus (HBV) infection and Stage 2 or greater chronic
      kidney disease who have received a liver transplant.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02862548</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>